CD8A and neoplasm: This team demonstrated that OV-IL15C plus EGFR-CAR NK cells synergistically inhibit tumor growth and improve survival in comparison to monotherapy, correlating with increased intracranial infiltration and activation of NK and CD8+T cells and increased persistence of CAR NK cells in an immunocompetent model (Ma et al., 2021).